SCHEDULE: Dermata CEO Proehl Updates 19.6% Stake

Dermata Therapeutics CEO Gerald T. Proehl filed an amendment to his Schedule 13D, confirming beneficial ownership of 19.6% of the company's common stock.

Summary

• Gerald T. Proehl, President and CEO of Dermata Therapeutics, Inc., beneficially owns an aggregate of 694,576 shares of the company's Common Stock.
• This ownership represents 19.6% of the 3,549,393 shares of Common Stock outstanding as of January 29, 2026.
• Mr. Proehl's holdings include 24 shares and stock options for 1,763 shares held directly, 79,950 shares and warrants for 11 shares held by Proehl Investment Ventures LLC (PIV), and 612,828 shares held by certain trusts for which he is trustee.
• The reported ownership excludes 41,070 shares underlying stock options and 78,740 shares underlying warrants that are not exercisable or vesting within sixty (60) days of the filing date.
• Warrants for 78,740 shares are not exercisable until the Issuer obtains stockholder approval of the transaction in which such warrants were issued.
• No purchases or sales of Common Stock or convertible securities were made by the Reporting Person since Amendment No. 8, filed on January 8, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive update, primarily a routine disclosure of a significant insider stake, which generally signals management confidence.

Positives

• The CEO, Gerald T. Proehl, maintains a significant beneficial ownership stake of 19.6% in Dermata Therapeutics, aligning his interests with shareholders.

Risks

• 78,740 shares underlying warrants held by Mr. Proehl are not exercisable until Dermata Therapeutics obtains stockholder approval of the transaction in which such warrants were issued.

Future Outlook

Warrants for 78,740 shares held by Mr. Proehl are not exercisable until Dermata Therapeutics obtains stockholder approval for the underlying transaction.

Industry Context

StockSavvy.ai notes that significant insider ownership, such as the CEO's 19.6% stake in Dermata Therapeutics, is often viewed positively by investors as it suggests strong alignment between management and shareholder interests, a common characteristic in smaller biotechnology or pharmaceutical firms where founders or key executives retain substantial equity.

Stakeholder Impact

• Shareholders: The continued significant ownership by the CEO may be seen as a positive signal of management's commitment and alignment with shareholder interests.

Next Steps

• Dermata Therapeutics needs to obtain stockholder approval for the transaction related to certain warrants held by Mr. Proehl to make them exercisable.

Key Dates

Keywords

Dermata Therapeutics, Gerald T. Proehl, Schedule 13D, Beneficial Ownership, Common Stock, CEO Stake, Insider Ownership, DRMA